Veristat, a scientific-minded globalclinical research organization (CRO), announced the expansion of its regulatory services capabilities by acquiring Drug Development and Regulation (DDR), a scientific and regulatory consultancy with offices in Barcelona and Amsterdam, and a CataloniaBio & HealthTech member.

Led by Founder and Chief Executive Officer, Xavier Luria, M.D.— former Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) — DDR has carved out an impressive growth trajectory working with small to midsized companies largely involved in rare diseases and cancers, among others, and keenly interested in avoiding the implications of a less than ideal regulatory path to registration of their drugs and medical technology products.

With the acquisition, DDR will allow Veristat to continue to deliver a flexible regulatory service model thatprovides end-to-end strategy, implementation and oversight of all related activities that ensure compliance with global regulatory requirements and swift approval. 

“Veristat exemplifies the core values DDR has embraced over the years,” stated Xavier Luria, M.D. “I am delighted to know that the company makes it a top priority to support and empower its people. Veristat is at the forefront of driving bold comprehensive clinical study strategies with a team unafraid of the big thinking required to get novel therapies to patients everywhere— quickly, safely and cost-effectively.”

Photo: Xavier Luria, CEO of DDR